During the past decade, Azienda Ospedaliera Sant Andrea conducted 62 clinical trials. In the 10-year time frame, 62 clinical trials started and 23 clinical trials were completed, i.e. on average, 37.1% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 16 clinical trials were completed. i.e. 64% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Ospedaliera Sant Andrea" #1 sponsor was "University of Roma La Sapienza" with 11 trials, followed by "Boehringer Ingelheim" with 9 trials sponsored, "Celgene" with 5 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored and "Janssen Research & Development, LLC" with 4 trials sponsored. Other sponsors include 61 different institutions and companies that sponsored additional 58 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliera Sant Andrea" #1 collaborator was "Eli Lilly and Company" with 5 trials as a collaborator, "1Med" with 1 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Associazione Medici Diabetologi (AMD)" with 1 trials as a collaborator and "Associazione Nazionale Medici Cardiologi Ospedalieri" with 1 trials as a collaborator. Other collaborators include 24 different institutions and companies that were collaborators in the rest 34 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliera Sant Andrea" are "Carcinoma, Non-Small-Cell Lung" (4 trials), "Myelodysplastic Syndromes" (4 trials), "Atrial Fibrillation" (3 trials), "Breast Cancer" (3 trials) and "Coronary Artery Disease" (3 trials). Many other conditions were trialed in "Azienda Ospedaliera Sant Andrea" in a lesser frequency.

Most popular intervention types in "Azienda Ospedaliera Sant Andrea" are "Drug" (66 trials), "Device" (11 trials), "Other" (11 trials), "Procedure" (7 trials) and "Biological" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Cisplatin" (3 trials), "Empagliflozin" (3 trials), "Gemcitabine" (3 trials) and "AVP-786" (2 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Ospedaliera Sant Andrea" are 94 trials for "All" genders, 3 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Azienda Ospedaliera Sant Andrea". undefined are not yet recruiting, 21 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 50 completed trials in Azienda Ospedaliera Sant Andrea, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Ospedaliera Sant Andrea, 1 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 48 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 7 trials that are defined as “Not Applicable".

Azienda Ospedaliera Sant Andrea has several departments that took part in Clinical trials: "Azienda Ospedaliera Sant'Andrea; UOC Neurologia" - 14 trials, "Ospedale Sant'Andrea Di Roma - U.O.C. Cardiologia" - 7 trials, "Aou Sant'Andrea - Roma - Uoc Ematologia" - 6 trials